| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5810095 | European Journal of Pharmaceutical Sciences | 2013 | 10 Pages |
Abstract
Tandutinib is a novel inhibitor of tyrosine kinases FLT3, PDGFR and KIT. Our study was to explore the capability of tandutinib to reverse ABC transporter-mediated multidrug resistance. Tandutinib reversed ABCG2-mediated drug resistance in ABCG2-482-R2, ABCG2-482-G2, ABCG2-482-T7 and S1-M1-80 cells and increased the accumulation of doxorubicin, rhodamine 123 and [H3] mitoxantrone in ABCG2-overexpressing cells. Importantly, tandutinib selectively sensitized side population cells to mitoxantrone. Taken together, our results advocate the potency of tandutinib as an ABCG2 modulator and stem-like cells targeted agent to increase efficiency of anticancer drugs.
Graphical abstractDownload high-res image (48KB)Download full-size image
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Xiao-qin Zhao, Chun-ling Dai, Shinobu Ohnuma, Yong-ju Liang, Wen Deng, Jun-Jiang Chen, Mu-Sheng Zeng, Suresh V. Ambudkar, Zhe-Sheng Chen, Li-Wu Fu,